Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus
In the face of diminishing therapeutic options for the treatment of infections caused by
multidrug-resistant, Gram-negative bacteria, clinicians are increasingly using colistin and …
multidrug-resistant, Gram-negative bacteria, clinicians are increasingly using colistin and …
International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical …
BT Tsuji, JM Pogue, AP Zavascki… - … : The Journal of …, 2019 - Wiley Online Library
The polymyxin antibiotics colistin (polymyxin E) and polymyxin B became available in the
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing position statements on polymyxin B and colistin clinical …
Recent data on polymyxin pharmacokinetics, pharmacodynamics, toxicity, and clinical
outcomes suggest these agents have limited clinical utility. Pharmacokinetics …
outcomes suggest these agents have limited clinical utility. Pharmacokinetics …
Polymyxin B: similarities to and differences from colistin (polymyxin E)
Hospital-acquired infections due to multidrug-resistant Gram-negative bacteria constitute
major health problems, since the medical community is continuously running out of available …
major health problems, since the medical community is continuously running out of available …
Colistin and polymyxin B: peas in a pod, or chalk and cheese?
Colistin and polymyxin B have indistinguishable microbiological activity in vitro, but they
differ in the form administered parenterally to patients. Polymyxin B is administered directly …
differ in the form administered parenterally to patients. Polymyxin B is administered directly …
Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance …
Objectives To comparatively evaluate the antimicrobial activities of colistin and polymyxin B
with those of other antimicrobials against a worldwide collection of 40 625 Gram-negative …
with those of other antimicrobials against a worldwide collection of 40 625 Gram-negative …
Agents of last resort: polymyxin resistance
The polymyxins, colistin (also known as polymyxin E) and polymyxin B, have a unique and
interesting history. Originally introduced in the 1950s for the treatment of infections due to …
interesting history. Originally introduced in the 1950s for the treatment of infections due to …
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Increasing multidrug resistance in Gram-negative bacteria, in particular Pseudomonas
aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, presents a critical …
aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, presents a critical …
Consistent global approach on reporting of colistin doses to promote safe and effective use
TO THE EDITOR—Colistin, an “old” polymyxin antibiotic, is being used increasingly as a last-
line therapy against infections caused by gram-negative bacteria that are resistant to other …
line therapy against infections caused by gram-negative bacteria that are resistant to other …
Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis
KZ Vardakas, ME Falagas - International journal of antimicrobial agents, 2017 - Elsevier
Colistin and polymyxin B (PMB) have different pharmacokinetic profiles and minor
differences in antimicrobial activities that may result in discrepancies in mortality and …
differences in antimicrobial activities that may result in discrepancies in mortality and …